NCT04784221撤回2 期
Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse: NANOPRO, a Non-randomized Phase II Study
Centre Francois Baclesse0 个研究点目标入组 46 人开始时间: 2021年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 46
- 主要终点
- Local efficacy of a treatment combining the administration of nanoparticles with proton therapy
研究概览
简要总结
This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously
详细描述
This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously in recurrent tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient aged 18 or over
- •Patient with tumor of the cephalo-spino-iliosacral axis corresponding to the spectrum of tumors treated in protontherapy, particularly base of the skull, pharyngeal wall, parapharyngeal and retropharyngeal lymph nodes, cavum without associated lymph node, pre-spinal tumor, etc. tumors are immobile as opposed to visceral thoracic, abdominal and pelvic tumors which may be mobile which will be excluded because they cannot be irradiated in proton therapy in the current state of the art),
- •Tumor already irradiated, within more than 6 months before inclusion
- •Patient with a relapse or a new tumor in irradiated territory
- •Tumor considered to be radioresistant (TCD50> 50Gy)
- •Dosimetry (s) of previous irradiations available
- •Progressive tumor in tissue already irradiated to at least 40 Gy EQD2 (α / β = 2)
- •Indication of reirradiation by protontherapy for curative purposes. The indication for reirradiation by protontherapy will be discussed depending on the size and location of the tumor (particularlyfor a volume of less than or equal to 113 ml of PTV in an ENT situation may be taken into account), the presence of previous toxicities. It will be validated by RCP at the Center François Baclesse
- •The patient may have received previous systemic treatment
- •Evaluable disease according to RECIST 1.1 criteria
- •Performance Status ≤ 2
- •Normal renal function: creatinine clearance ≥ 50 ml / min
- •Patient affiliated to a social security system
- •Patient having given written consent
排除标准
- •Mobile tumors
- •Lymphomas, brain tumors (gliomas), meningiomas, skin carcinomas, malignant melanomas (skin or mucous membranes), tumor of the larynx, mobile lesions of the oral cavity
- •Recurrence occurring within 6 months of the end of the first irradiation
- •Patient with a contraindication to radiotherapy
- •Patient with progressive visceral or cerebral metastases
- •Life-threatening comorbidities within two years
- •Patient with a contraindication to MRI
- •Immovable metallic material in the target volume (significant imaging artefacts)
- •Impossibility of completely immobilizing the target volume (moving organ)
- •Large volume to be irradiated (PTV) for an acceptable benefit / risk balance evaluated in RCP of the François Baclesse Center
- •Neoplasic skin ulceration
- •Doses previously received by OARs or radiation toxicity already present preventing reirradiation including in protontherapy (clinical and dosimetric study of each case)
- •Concomitant cancer treatment such as chemotherapy, immunotherapy, targeted therapy or other, underway or planned to be initiated during irradiation
- •Simultaneous participation in another therapeutic clinical trial
- •Patient deprived of liberty, under guardianship or curatorship
- •Pregnant or breastfeeding patient
- •Patient unable to undergo medical monitoring of the trial for geographic, social or psychopathological reasons
- •History of other malignant disease in the past 3 years, except skin cancer other than melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and not show signs of recurrence for at least 3 years
结局指标
主要结局
Local efficacy of a treatment combining the administration of nanoparticles with proton therapy
时间窗: 2 years after the treatment
proportion of patients alive and without local progression two years after the start of proton therapy (local progression-free survival rate)
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular CarcinomaHepatocellular CarcinomaNCT02395523National Cancer Center, Korea45
已完成
不适用
Hypofractionated Proton Beam Radiotherapy for Hepatocellular CarcinomaHepatocellular CarcinomaNCT01643824National Cancer Center, Korea112
终止
不适用
Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate CancerLow Risk Prostate CancerIntermediate Risk Prostate CancerNCT03740191EBG MedAustron GmbH5
进行中（未招募）
2 期
Hypofractionated Proton Beam Therapy for Localized Prostate CancerStage I Prostate Adenocarcinoma AJCC v7Stage II Prostate Adenocarcinoma AJCC v7NCT01950351M.D. Anderson Cancer Center241
终止
1 期
Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT01565772Massachusetts General Hospital4